Degludec

PreclinicalSmall molecule

Eli Lilly

Degludec is one of 8 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic KetoacidosisActive, not recruiting

Diabetic KetoacidosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Diabetic Ketoacidosis

#DrugCompanyPhaseTrials

Reamberin

PPOLYSAN Scientific & Technological Pharmaceutical Company

Phase 3

1 2

Jardiance

Boehringer Ingelheim

Preclinical

1 3

Glargine

Eli Lilly

Preclinical

3 4

DPP-4 Inhibitors

Boehringer Ingelheim

Preclinical

1 5

Sodiumchloride

RRadboud University Medical Center

Preclinical

1 6

Degludec

Eli Lilly

Preclinical

1 7

IV Insulin

RRush University Medical Center

Preclinical

1 8

IV Fluid Repletion

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Diabetes Mellitus, Type 2

NCT07215312

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Unknown status·—·Phase 4·NCT04664764·60 enrolled

Type 2 Diabetes1 trial

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT03336528·180 enrolled

Diabetic Ketoacidosis1 trial

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Terminated·HHennepin Healthcare Research Institute·N/A·NCT03001323·27 enrolled

Cardiovascular1 trial

Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

Completed·UUniversity of Split, School of Medicine·Phase 4·NCT04692415·25 enrolled

Diabetes Mellitus, Type 21 trial

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07215312·100 enrolled

1 more indication

Unspecified1 trial

Degludec Glargine U300 Hospital Study

Completed·MMedanta, The Medicity, India·N/A·NCT05036876·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Degludec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Degludec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Degludec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Eli Lilly

Degludec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 1 Diabetes1 trial

Type 2 Diabetes1 trial

Diabetic Ketoacidosis1 trial

Cardiovascular1 trial

Diabetes Mellitus, Type 21 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News